| Date |
Title |
|
| 06/22/20 |
Akorn Animal Health Announces Launch of Neomycin and Polymyxin B Sulfates, and Bacitracin Zinc Ophthalmic Ointment
LAKE FOREST, Ill., June 22, 2020 (GLOBE NEWSWIRE) -- Akorn, Inc. (OTC Pink Market: AKRXQ), a leading specialty generic pharmaceutical company, today announced the launch of its Abbreviated New Animal Drug Application (ANADA) for Neomycin and Polymyxin B Sulfates, and Bacitracin Zinc Ophthalmic
|
|
| 05/20/20 |
Akorn to Use Voluntary Chapter 11 Process to Position Business for Long-Term Success
Continues Operations as Usual, Delivering Safe and Effective Products to Customers and Patients LAKE FOREST, Ill. , May 20, 2020 /PRNewswire/ -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company ("Akorn" or the "Company"), today announced that the Company and its U.S.
|
|
| 05/11/20 |
Akorn Provides First Quarter 2020 Results
LAKE FOREST, Ill. , May 11, 2020 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced its financial results for the first quarter of 2020. First Quarter 2020 Results and Recent Developments Net revenue was $205 million , up $39 million , 23%
|
|
| 04/01/20 |
Akorn Provides Update on Sale Process
LAKE FOREST, Ill. , April 1, 2020 /PRNewswire/ -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced that it no longer has any bids in the Sale Process that are sufficient to pay all obligations under its term loan agreement.
|
|
| 02/26/20 |
Akorn Provides Fourth Quarter and Full Year 2019 Results
LAKE FOREST, Ill. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced its financial results for the quarter and year ended December 31, 2019 . Fourth Quarter 2019 Results and Recent Developments Net revenue was $162 million ,
|
|
| 02/12/20 |
Akorn Announces New Extension of Standstill with Lenders and Agrees to Pursue a Sale of its Business
LAKE FOREST, Ill. , Feb. 12, 2020 /PRNewswire/ -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today announced it has reached an agreement with certain of its lenders to extend the standstill period. The agreement defines a path forward and outlines milestones to execute
|
|
| 02/10/20 |
Akorn Continues Negotiations with Lenders
LAKE FOREST, Ill. , Feb. 10, 2020 /PRNewswire/ -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty pharmaceutical company, today confirmed that negotiations with certain of its lenders are ongoing following the expiration of its standstill agreement on February 7, 2020 .
|
|
|
